Advertisement

Pharmacy World and Science

, Volume 17, Issue 4, pp 133–137 | Cite as

Bromocriptine and suppression of postpartum lactation

The incidence of adverse cardiovascular effects in women of childbearing age
  • R. M. C. Herings
  • B. H. C. Stricker
Articles

Abstract

The use of bromocriptine for the suppression of postpartum lactation drew widespread attention to a potentially increased risk for cardiovascular and cerebrovascular adverse effects. To estimate the incidence of these events a follow-up study was performed among 2,130 women of 15–44 years of age who were treated with a course of bromocriptine in 1990–1992. None of these women were admitted to the hospital for cardiovascular or cerebrovascular events. However, the incidence of pregnancy hypertension and the use of cardiovascular drugs increased considerably in the last 2 months before delivery. Therefore, cardiovascular or cerebrovascular events can probably be explained by pre-existing morbidity rather than by the use of bromocriptine. We estimated, using a ‘worst-case’ analysis, that fewer than 2 Dutch women each year would develop serious cardiovascular or cerebrovascular events.

Keywords

Adverse effects Bromocriptine Cardiovascular diseases Cerebrovascular disorders Incidence Lactation Product surveillance, postmarketing 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Postpartum hypertension, seizures, strokes reported with bromocriptine. FDA Drug Bull 1984;14(1):3–4.Google Scholar
  2. 2.
    Katz M, Kroll D, Pak I, Osimoni A, Hirsch M. Puerpual hypertension, stroke, and seizures after suppression of lactation with bromocriptine. Obstet Gynecol 1985;66(6):822–4.PubMedGoogle Scholar
  3. 3.
    Iffy L, Ten Hove W, Frisoli G. Acute myocardial infarction in the puerperium in patients receiving bromocriptine. Am J Obstet Gynecol 1986;155(2):371–2.PubMedGoogle Scholar
  4. 4.
    Ruch A, Duhring JL. Postpartum myocardial infarction in a patient receiving bromocriptine. Obstet Gynecol 1989:74(3 pt 2):448–51.PubMedGoogle Scholar
  5. 5.
    Gittelman DK. Bromocriptine associated with postpartum hypertension, seizures, and pituitary hemorrhage. Gen Hosp Psychiatry 1991;13(4):278–80.PubMedGoogle Scholar
  6. 6.
    Eickman FM. Recurrent myocardial infarction in a postpartum patient receiving bromocriptine. Clin Cardiol 1992;15(10):781–3.PubMedGoogle Scholar
  7. 7.
    Larrazet F, Spaulding C, Lobreau HJ, Weber S, Guerin F. Possible bromocriptine-induced myocardial infarction. Ann Intern Med 1993;118(3):199–200.PubMedGoogle Scholar
  8. 8.
    FDA to act on Sandoz Parlodel®. Scrip 1993;1855:10.Google Scholar
  9. 9.
    Woodcock J. Bromocriptine mesylate: withdrawal of approval of the indication for the prevention of physiological lactation. Fed Reg 1995;60(19):3404–5.Google Scholar
  10. 10.
    Herings RMC. PHARMO: a record linkage system for postmarketing surveillance of prescription drugs in the Netherlands [dissertation]. Utrecht: Utrecht University, 1993.Google Scholar
  11. 11.
    Anatomical Therapeutic Chemical (ATC) classification index: Including defined daily doses (DDD) for plain substances. Oslo: World Health Organization, 1992.Google Scholar
  12. 12.
    WHO. International Classification of Diseases. 9th Clinical Modification (ICD-9-CM). Geneva: World Health Organization, 1987.Google Scholar
  13. 13.
    Vademecum of health statistics of the Netherlands 1993. ′s-Gravenhage: Netherlands Central Bureau of Statistics & Ministry of Welfare, Health and Cultural Affairs, 1993.Google Scholar
  14. 14.
    Fournié A, Graille V, Montastruc JL. Bromocriptine, lactation inhibition and pharmacovigilance. J Gynecol Obstet Biol Reprod 1994;23:129–30.Google Scholar
  15. 15.
    Watson DL, Bhatia RK, Norman GS, Brindley BA, Sokol RJ. Bromocriptine mesylate for lactation suppression: a risk for postpartum hypertension. Obstet Gynecol 1989;74(4):573–6.PubMedGoogle Scholar
  16. 16.
    Vandenbroucke JP, Hofman A. Grondslagen der epidemiologie [Fundamentals of epidemiology]. Utrecht: Bunge, 1993.Google Scholar
  17. 17.
    Healey M. Suppressing lactation with oral diuretics [letter]. Lancet 1961:1353–4.Google Scholar
  18. 18.
    De Jong-van den Berg LTW. Drug utilization studies in pregnancy: what can they contribute to safety assessment? [dissertation]. Groningen: University of Groningen, 1992.Google Scholar

Copyright information

© Royal Dutch Association for Advancement of Pharmacy 1995

Authors and Affiliations

  • R. M. C. Herings
    • 1
  • B. H. C. Stricker
    • 2
  1. 1.Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, Faculty of PharmacyUtrecht UniversityTB Utrechtthe Netherlands
  2. 2.Pharmacoepidemiology Unit. Department of Internal Medicine II, University Hospital DijkzigtErasmus University RotterdamRotterdamthe Netherlands

Personalised recommendations